医療用分析検査サービス市場 : 2029年までの世界予測

出版：MarketsandMarkets（マーケッツアンドマーケッツ）　出版年月：2024年4月

Healthcare Analytical Testing Services Market – Forecast to 2029

医療用分析検査サービス市場 : タイプ（バイオマーカー試験、安定性試験、原材料試験、バッチリリース試験、洗浄バリデーション）、エンドユーザー（製薬会社、医療機器会社）、地域別の規模 – 2029年までの世界予測
Healthcare Analytical Testing Services Market Size by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation), End User (Pharmaceutical Companies, Medical Device Companies) & Region – Global Forecast to 2029

お問合せ・ご注文　　出版社・価格・納期について

Report Overview

The Healthcare analytical testing services Market is projected to reach USD 12.6 billion by 2029 from USD 7.4 billion in 2024, at a CAGR of 11.2% during the forecast period.

医療用分析検査サービス市場は、予測期間中に11.2%のCAGRで、2024年の74億米ドルから2029年までに126億米ドルに達すると予測されています。

The growth of the healthcare analytical testing services market is fueled by increasing demand across industries for quality assurance and regulatory compliance. Challenges in developing precise analytical techniques provide opportunities for service providers, while government initiatives encourage investment and innovation. These factors drive market expansion globally, alongside trends such as outsourcing due to pricing concerns and the development of innovative medicines. Expansion into new locations also boosts demand for specific tests, further driving the need for healthcare analytical testing services.

“Biohealthcare analytical testing services segment accounted for a substantial share of the healthcare analytical testing services market, by type in 2023.”
The Biohealthcare analytical testing services segment is expected to account for the largest share of 37.1% of the global Healthcare analytical testing services Market in 2023. It is projected to grow at the highest CAGR of 10.7% during the forecast period. The healthcare analytical testing services market is segmented by type into various categories, including bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, genomic services, and environmental monitoring services. In 2023, the biohealthcare analytical testing services segment stood out as the largest, primarily due to its comprehensive offerings tailored to different drug types like vaccines, small molecules, and biologics. This extensive range of services meets the diverse requirements of pharmaceutical and biopharmaceutical companies, thereby driving the segment’s substantial market share.

“The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market”
Based on bioanalytical service types type, the market encompasses cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and other biohealthcare analytical testing services. In 2023, the cell-based assays segment emerged as the market leader. This dominance is attributed to the growing preference for cell-based assays in high-throughput screening, as they offer pertinent in vivo biological insights compared to biochemical assays. This advantage accelerates the drug discovery process, thus contributing to the segment’s prominence.

“North America to witness the substantial growth rate during the forecast period.”
North America commands the largest share in the healthcare analytical testing services market, outstripping other regions such as Europe, Asia Pacific, Latin America, and the Middle East & Africa. This dominance is primarily fueled by the burgeoning number of biopharmaceutical and pharmaceutical companies based in the United States. Moreover, the US market benefits from the strong foothold of well-established players, which further propels the market’s growth trajectory. The region’s advanced infrastructure, supportive regulatory environment, and emphasis on research and development also contribute significantly to its leadership position in the global healthcare analytical testing services market.

The break-down of primary participants is as mentioned below:
• By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
• By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%

Key Players in the Healthcare analytical testing services Market
The prominent players in the global healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Medpace Holdings, Inc. (US), LGC Limited (Cinven) (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), BioAgilytix Labs (US), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), and Syneos Health, INC (US).

Research Coverage:
The report analyzes the Healthcare analytical testing services Market and aims to estimate the market size and future growth potential of various market segments, based on type, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:
 Analysis of Market Dynamics (Stringent regulatory landscape, growing focus on analytical testing of bilogics and biomilars, rising investments in pharma and biopharma R & D), restraints (Increasing Preassure on market players due to rising cost and market competition), opportunities (Adoption of new technologies, supporting government initiatives), and challenges (increasing need for improvement of sentsitivity of bioanalytical methods)
 Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Healthcare analytical testing services market.
 Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

Table of Contents

1            INTRODUCTION            50

1.1         STUDY OBJECTIVES      50

1.2         MARKET DEFINITION   50

1.2.1      INCLUSIONS & EXCLUSIONS     51

1.2.2      MARKET SEGMENTATION         52

FIGURE 1           MARKETS COVERED     52

1.2.3      REGIONS COVERED      53

FIGURE 2           REGIONAL SEGMENTATION     53

1.2.4      YEARS CONSIDERED     53

1.3         CURRENCY CONSIDERED          54

1.4         LIMITATIONS   54

1.4.1      METHODOLOGY-RELATED LIMITATIONS         54

1.4.2      SCOPE-RELATED LIMITATIONS             54

1.5         STAKEHOLDERS            54

1.6         SUMMARY OF CHANGES            55

2            RESEARCH METHODOLOGY     56

2.1         RESEARCH DATA           56

2.2         RESEARCH METHODOLOGY DESIGN    56

FIGURE 3           RESEARCH DESIGN       56

2.2.1      SECONDARY RESEARCH             57

2.2.1.1   Key data from secondary sources     58

2.2.2      PRIMARY DATA 58

FIGURE 4           PRIMARY SOURCES       59

2.2.2.1   Key data from primary sources         60

2.2.2.2   Insights from primary experts          60

FIGURE 5           BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 61

FIGURE 6           BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION    61

2.3         MARKET SIZE ESTIMATION METHODOLOGY    62

FIGURE 7           MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS              62

FIGURE 8           REVENUE SHARE ANALYSIS: COMPANY ILLUSTRATION 63

FIGURE 9           REVENUE SHARE ANALYSIS ILLUSTRATION      63

FIGURE 10         TOP-DOWN APPROACH             64

FIGURE 11         CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       65

FIGURE 12         CAGR PROJECTIONS     65

2.4         DATA TRIANGULATION PROCEDURE   67

FIGURE 13         DATA TRIANGULATION METHODOLOGY         67

2.5         MARKET SHARE ESTIMATION   68

2.6         STUDY ASSUMPTIONS  68

2.7         RISK ASSESSMENT         68

TABLE 1             RISK ASSESSMENT ANALYSIS    68

2.8         RECESSION IMPACT ANALYSIS 69

3            EXECUTIVE SUMMARY 70

FIGURE 14         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)       70

FIGURE 15         BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)             71

FIGURE 16         PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)  72

FIGURE 17         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)            73

FIGURE 18         GEOGRAPHICAL SNAPSHOT OF HEALTHCARE ANALYTICAL TESTING SERVICES MARKET     74

4            PREMIUM INSIGHTS      75

4.1         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW              75

FIGURE 19         GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH      75

4.2         EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE AND COUNTRY (2023)      76

FIGURE 20         BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023    76

4.3         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         77

FIGURE 21         CHINA, INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       77

4.4         REGIONAL MIX: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2022–2029)     78

FIGURE 22         APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2022–2029)      78

4.5         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEVELOPED VS. EMERGING ECONOMIES (2024 VS. 2029)       79

FIGURE 23         EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD       79

5            MARKET OVERVIEW     80

5.1         INTRODUCTION            80

5.2         MARKET DYNAMICS     80

FIGURE 24         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    80

5.2.1      DRIVERS            81

5.2.1.1   Stringent regulatory guidelines        81

5.2.1.2   Growing focus on analytical testing of biologics & biosimilars    82

TABLE 2             PATENT EXPIRY OF BEST-SELLING BIOLOGICS 82

5.2.1.3   Increasing outsourcing of analytical testing by pharmaceutical & medical device companies           82

5.2.1.4   Increasing number of clinical trials   83

FIGURE 25         INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2004–2024)       83

FIGURE 26         PERCENTAGE OF REGISTERED STUDIES BY LOCATION (AS OF MARCH 08, 2024)            84

5.2.1.5   Growing R&D expenditure in pharmaceutical & biopharmaceutical industry              84

FIGURE 27         PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2002–2022          84

5.2.1.6   Rising acceptance of quality-by-design approach in pharmaceutical research & manufacturing     85

TABLE 3             IMPACT ANALYSIS: DRIVERS     85

5.2.2      RESTRAINTS     86

5.2.2.1   Increasing pressure on market players due to rising costs and market competition              86

TABLE 4             IMPACT ANALYSIS: RESTRAINTS            86

5.2.3      OPPORTUNITIES           87

5.2.3.1   Adoption of new techniques and technologies 87

5.2.3.2   Growing focus on emerging economies          87

TABLE 5             IMPACT ANALYSIS: OPPORTUNITIES    88

5.2.4      CHALLENGES   88

5.2.4.1   Shortage of skilled professionals      88

5.2.4.2   Specific requirements for innovative formulations and medical devices    89

5.2.4.3   Need to improve sensitivity of bioanalytical methods   89

TABLE 6             IMPACT ANALYSIS: CHALLENGES          90

5.3         ECOSYSTEM ANALYSIS 90

TABLE 7             HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ROLE IN ECOSYSTEM    90

FIGURE 28         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM ANALYSIS 91

5.4         VALUE CHAIN ANALYSIS            91

FIGURE 29         VALUE CHAIN ANALYSIS            91

5.5         CASE STUDY ANALYSIS 92

5.5.1      UNLOCKING BIOPHARMACEUTICAL DEVELOPMENT POTENTIAL THROUGH OUTSOURCING ANALYTICAL TESTING        92

5.5.2      REVOLUTIONIZING PHARMACEUTICAL TESTING: A CASE STUDY IN ANALYTICAL TESTING EVOLUTION      92

5.6         PORTER’S FIVE FORCES ANALYSIS         92

TABLE 8             PORTER’S FIVE FORCES ANALYSIS         92

FIGURE 30         PORTER’S FIVE FORCES ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET     93

5.6.1      THREAT OF NEW ENTRANTS    93

5.6.2      BARGAINING POWER OF SUPPLIERS     93

5.6.3      INTENSITY OF COMPETITIVE RIVALRY 94

5.6.4      BARGAINING POWER OF BUYERS           94

5.6.5      THREAT OF SUBSTITUTES         94

5.7         REGULATORY LANDSCAPE       95

5.7.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          95

TABLE 9             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         95

TABLE 10           EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         95

TABLE 11           ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         95

TABLE 12           LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         96

TABLE 13           MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         96

5.7.2      REGULATORY ANALYSIS            96

TABLE 14           ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS              97

TABLE 15           OVERVIEW OF GUIDELINES OF LABORATORY SERVICES              98

5.7.3      NORTH AMERICA          98

5.7.4      EUROPE             99

TABLE 16           DEVELOPMENT OF GLP ACROSS COUNTRIES   99

TABLE 17           REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES  99

5.7.5      ASIA PACIFIC    100

5.8         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100

FIGURE 31         REVENUE SHIFT AND NEW POCKETS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET        101

5.9         KEY CONFERENCES & EVENTS, 2024–2025           101

TABLE 18           HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS         101

5.10       INVESTMENT AND FUNDING SCENARIO            102

FIGURE 32         NUMBER OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018–2022            102

FIGURE 33         VALUE OF INVESTOR DEALS IN HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY KEY PLAYER, 2018-2022             103

5.11       KEY STAKEHOLDERS & BUYING CRITERIA          103

5.11.1    KEY STAKEHOLDERS IN BUYING PROCESS         103

FIGURE 34         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 103

TABLE 19           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS       104

5.11.2    BUYING CRITERIA         104

FIGURE 35         KEY BUYING CRITERIA FOR END USERS              104

TABLE 20           KEY BUYING CRITERIA FOR END USERS              105

6            HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE              106

6.1         INTRODUCTION            107

TABLE 21           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             107

6.2         BIOANALYTICAL TESTING        107

TABLE 22           BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     108

TABLE 23           BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          108

6.2.1      PHARMACOKINETIC & TOXICOKINETIC TESTING          109

6.2.1.1   Increasing number of clinical trials for drug development to propel growth              109

TABLE 24           PHARMACOKINETIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          109

6.2.2      IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING       110

6.2.2.1   Increasing requirement for drug safety approvals to support market growth              110

TABLE 25           IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        111

6.2.3      BIOMARKER TESTING  111

6.2.3.1   Rising need for specialized drug development to drive market    111

TABLE 26           BIOMARKER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     112

6.2.4      BIOASSAY TESTING       112

6.2.4.1   Growing adoption of high-content screening for cytotoxicity testing to fuel growth              112

TABLE 27           BIOASSAY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 113

6.2.5      OTHER BIOANALYTICAL TESTING SERVICES    113

TABLE 28           OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       114

6.3         PHYSICAL CHARACTERIZATION            114

TABLE 29           PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          115

TABLE 30           PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       115

6.3.1      LASER PARTICLE SIZE ANALYSIS            116

6.3.1.1   Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market           116

TABLE 31           LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       116

6.3.2      THERMAL ANALYSIS     117

6.3.2.1   Advancements in thermal analysis techniques to support growth              117

TABLE 32           THERMAL ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 117

6.3.3      OPTICAL CHARACTERIZATION 117

6.3.3.1   Growing complexity of biological structures to contribute to growth        117

TABLE 33           OPTICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       118

6.3.4      SURFACE AREA ANALYSIS          118

6.3.4.1   Growing need for surface analysis to streamline drug development processes to fuel growth          118

TABLE 34           SURFACE AREA ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          119

6.3.5      OTHER PHYSICAL CHARACTERIZATION SERVICES        119

TABLE 35           OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)  120

6.4         METHOD DEVELOPMENT & VALIDATION         120

TABLE 36           METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       121

TABLE 37           METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)  121

6.4.1      EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION    122

6.4.1.1   Growing development of parenterally administered drugs and biologic products to drive market        122

TABLE 38           EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)              122

6.4.2      PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION 123

6.4.2.1   Rising emphasis on impurity testing to boost market    123

TABLE 39           PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        123

6.4.3      STABILITY-INDICATING METHOD VALIDATION            124

6.4.3.1   Need to ensure safety and efficacy of therapeutic drugs to spur growth    124

TABLE 40           STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)            124

6.4.4      CLEANING VALIDATION & METHOD DEVELOPMENT   124

6.4.4.1   Growing needs to evaluate cleaning practices and ensure complete decontamination to fuel growth       124

TABLE 41           CLEANING VALIDATION & METHOD DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        125

6.4.5      ANALYTICAL STANDARD CHARACTERIZATION 125

6.4.5.1   Growing importance of analytical standard characterization in drug development to support market 125

TABLE 42           ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)            126

6.4.6      TECHNICAL CONSULTING        126

6.4.6.1   Need for regulatory approvals for drug development to drive market        126

TABLE 43           TECHNICAL CONSULTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          127

6.4.7      OTHER METHOD DEVELOPMENT & VALIDATION SERVICES     127

TABLE 44           OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)            128

6.5         RAW MATERIAL TESTING          128

TABLE 45           RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     129

TABLE 46           RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          129

6.5.1      COMPLETE COMPENDIAL TESTING      129

6.5.1.1   Need to determine efficacy and safety of therapeutic products to drive growth              129

TABLE 47           COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       130

6.5.2      CONTAINER TESTING  130

6.5.2.1   Need to optimize sealing and evaluate temperature impact to fuel growth 130

TABLE 48           CONTAINER TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     131

6.5.3      HEAVY METAL TESTING            131

6.5.3.1   Implementation of various techniques and technologies for heavy metal testing to aid growth           131

TABLE 49           HEAVY METAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     132

6.5.4      WATER CONTENT ANALYSIS    132

6.5.4.1   Need to check for water content in pharmaceutical products to support growth              132

TABLE 50           WATER CONTENT ANALYSIS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          133

6.5.5      OTHER RAW MATERIAL TESTING SERVICES      133

TABLE 51           OTHER RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       133

6.6         BATCH-RELEASE TESTING SERVICES    134

TABLE 52           BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     134

TABLE 53           BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          135

6.6.1      DISSOLUTION TESTING             135

6.6.1.1   Wide usage of dissolution testing in formulation development and manufacturing to drive growth    135

TABLE 54           DISSOLUTION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     136

6.6.2      ELEMENTAL IMPURITY TESTING           136

6.6.2.1   Need to minimize cost of in-house analysis and labor to fuel growth        136

TABLE 55           ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       137

6.6.3      DISINTEGRATION TESTING      137

6.6.3.1   Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth   137

TABLE 56           BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA       138

TABLE 57           DISINTEGRATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          138

6.6.4      HARDNESS TESTING     139

6.6.4.1   Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth  139

TABLE 58           HARDNESS TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     139

6.6.5      FRIABILITY TESTING    140

6.6.5.1   Need to measure resistance of tablets and granules to abrasion or fracture to support market    140

TABLE 59           FRIABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     140

6.6.6      OTHER BATCH-RELEASE TESTING SERVICES    140

TABLE 60           OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       141

6.7         STABILITY TESTING     141

TABLE 61           STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 142

TABLE 62           STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 142

6.7.1      DRUG SUBSTANCE STABILITY TESTING             142

6.7.1.1   Regulatory requirements for drug approval to drive market        142

TABLE 63           DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       143

6.7.2      FORMULATION EVALUATION STABILITY TESTING       143

6.7.2.1   Need to analyze and predict shelf life of products to drive demand           143

TABLE 64           FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)            144

6.7.3      ACCELERATED STABILITY TESTING     144

6.7.3.1   Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth          144

TABLE 65           ACCELERATED STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       145

6.7.4      PHOTOSTABILITY TESTING      145

6.7.4.1   Need for robust photostability testing process to ensure product quality and safety to drive adoption 145

TABLE 66           PHOTOSTABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          146

6.7.5      FORCED DEGRADATION TESTING        146

6.7.5.1   Regulatory requirements and need for comprehensive stability testing in pharmaceutical industry to boost market        146

TABLE 67           FORCED DEGRADATION TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       147

6.7.6      OTHER STABILITY TESTING SERVICES 147

TABLE 68           OTHER STABILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          147

6.8         MICROBIAL TESTING    148

TABLE 69           MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 148

TABLE 70           MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     149

6.8.1      MICROBIAL LIMIT TESTING      149

6.8.1.1   Need to determine whether products comply with compendial specifications for microbial quality to boost adoption  149

TABLE 71           STANDARD LIMITS FOR MICROBIAL LIMIT TESTING     150

TABLE 72           MICROBIAL LIMIT TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          150

6.8.2      VIROLOGY TESTING     150

6.8.2.1   Increasing outbreaks of viral diseases to drive market   150

TABLE 73           VIROLOGY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 151

6.8.3      STERILITY TESTING      151

6.8.3.1   Rising development of parenteral preparations and immunological products to drive market        151

TABLE 74           STERILITY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 152

6.8.4      ENDOTOXIN TESTING  152

6.8.4.1   Need to standardize procedures and follow regulatory guidelines to support demand 152

TABLE 75           ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     153

6.8.5      PRESERVATIVE EFFICACY TESTING       153

6.8.5.1   Need to ensure product safety for product approval to support growth     153

TABLE 76           PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       154

6.8.6      OTHER MICROBIAL TESTING SERVICES             154

TABLE 77           OTHER MICROBIAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          155

6.9         GENOMIC TESTING SERVICES  155

6.9.1      NEED TO GAIN INSIGHTS INTO DISEASE MECHANISMS AND TREATMENT RESPONSES TO BOOST MARKET  155

TABLE 78           GENOMIC TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 156

6.10       OTHER ANALYTICAL TESTING SERVICES           156

TABLE 79           OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)          156

7            HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER    157

7.1         INTRODUCTION            158

TABLE 80           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)    158

7.2         PHARMACEUTICAL COMPANIES            158

7.2.1      INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH          158

FIGURE 36         R&D SPENDING OF PHARMA MEMBER COMPANIES, 2020–2022              159

TABLE 81           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)              160

7.3         BIOPHARMACEUTICAL COMPANIES     160

7.3.1      GROWING INVESTMENTS IN BIOPHARMACEUTICAL COMPANIES TO BOOST MARKET GROWTH        160

TABLE 82           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)              161

7.4         MEDICAL DEVICE COMPANIES 161

7.4.1      STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH          161

TABLE 83           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022–2029 (USD MILLION) 162

7.5         HOSPITALS & CLINICS  162

7.5.1      GROWING PREVALENCE OF CHRONIC DISEASES TO FAVOR MARKET GROWTH          162

TABLE 84           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)  163

7.6         FORENSIC LABS             163

7.6.1      GROWING USE OF ANALYTICAL TESTING IN FORENSIC LABS TO BOOST MARKET GROWTH        163

TABLE 85           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR FORENSIC LABS, BY REGION, 2022–2029 (USD MILLION) 164

7.7         COSMETIC & NUTRACEUTICAL COMPANIES     164

7.7.1      STRINGENT GUIDELINES FOR QUALITY CONTROL TO DRIVE MARKET              164

TABLE 86           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR COSMETIC & NUTRACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)          165

8            HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION       166

8.1         INTRODUCTION            167

FIGURE 37         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC SNAPSHOT          167

TABLE 87           HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)       168

8.2         NORTH AMERICA          168

8.2.1      NORTH AMERICA: RECESSION IMPACT 168

FIGURE 38         NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET        169

TABLE 88           NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     170

TABLE 89           NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 170

TABLE 90           NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    171

TABLE 91           NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    171

TABLE 92           NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 172

TABLE 93           NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    172

TABLE 94           NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    173

TABLE 95           NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             173

TABLE 96           NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       174

TABLE 97           NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     174

8.2.2      US         175

8.2.2.1   High number of pre-registration drugs in pipeline to drive market           175

FIGURE 39         US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2021)       175

TABLE 98           US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       176

TABLE 99           US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          176

TABLE 100         US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             177

TABLE 101         US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    177

TABLE 102         US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          178

TABLE 103         US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          178

TABLE 104         US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     179

TABLE 105         US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     179

8.2.3      CANADA            180

8.2.3.1   Presence of well-established CROs to support market growth    180

FIGURE 40         CANADA: ONGOING CLINICAL TRIALS, BY THERAPEUTIC AREA (2023)      180

TABLE 106         CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    181

TABLE 107         CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             181

TABLE 108         CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       182

TABLE 109         CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    182

TABLE 110         CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             183

TABLE 111         CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             183

TABLE 112         CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          184

TABLE 113         CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          184

8.3         EUROPE             185

8.3.1      EUROPE: RECESSION IMPACT   185

TABLE 114         EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         186

TABLE 115         EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    186

TABLE 116         EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             187

TABLE 117         EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       187

TABLE 118         EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    188

TABLE 119         EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             188

TABLE 120         EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             189

TABLE 121         EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          189

TABLE 122         EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          190

TABLE 123         EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)         190

8.3.2      GERMANY         191

8.3.2.1   Government support and flexible labor laws make Germany favorable location for clinical trials        191

TABLE 124         GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    192

TABLE 125         GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             192

TABLE 126         GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    193

TABLE 127         GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193

TABLE 128         GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             194

TABLE 129         GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             194

TABLE 130         GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          195

TABLE 131         GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          195

8.3.3      FRANCE             196

8.3.3.1   Favorable government regulations to drive market       196

TABLE 132         FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    197

TABLE 133         FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             197

TABLE 134         FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       198

TABLE 135         FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    198

TABLE 136         FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             199

TABLE 137         FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             199

TABLE 138         FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          200

TABLE 139         FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          200

8.3.4      UK         201

8.3.4.1   Investments by pharmaceutical sponsors for drug discovery services to support growth   201

TABLE 140         UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       201

TABLE 141         UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          202

TABLE 142         UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             202

TABLE 143         UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    203

TABLE 144         UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          203

TABLE 145         UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          204

TABLE 146         UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     204

TABLE 147         UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     205

8.3.5      ITALY   205

8.3.5.1   Low drug approval time to support market growth       205

TABLE 148         ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    206

TABLE 149        ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          206

TABLE 150         ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             207

TABLE 151         ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    207

TABLE 152         ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          208

TABLE 153        ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          208

TABLE 154         ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     209

TABLE 155         ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          209

8.3.6      SWITZERLAND 210

8.3.6.1   Large and growing pharma production volume to drive demand for analytical testing services    210

TABLE 156         SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 210

TABLE 157         SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       211

TABLE 158         SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    211

TABLE 159         SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 212

TABLE 160         SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       212

TABLE 161         SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       213

TABLE 162         SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             213

TABLE 163         SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             214

8.3.7      SPAIN   214

8.3.7.1   Rising R&D expenditure to boost growth       214

TABLE 164         SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    215

TABLE 165        SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          215

TABLE 166         SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             216

TABLE 167         SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    216

TABLE 168         SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          217

TABLE 169        SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          217

TABLE 170         SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     218

TABLE 171         SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          218

8.3.8      REST OF EUROPE           219

TABLE 172         REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 220

TABLE 173         REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    220

TABLE 174         REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    221

TABLE 175         REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 221

TABLE 176         REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    222

TABLE 177         REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    222

TABLE 178         REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             223

TABLE 179         REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             223

8.4         ASIA PACIFIC    224

8.4.1      ASIA PACIFIC: RECESSION IMPACT        224

FIGURE 41         ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT     225

TABLE 180         ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)         226

TABLE 181         ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    226

TABLE 182         ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       227

TABLE 183         ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    227

TABLE 184         ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 228

TABLE 185         ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             228

TABLE 186         ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       229

TABLE 187         ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             229

TABLE 188         ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             230

TABLE 189         ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)         230

8.4.2      CHINA  231

8.4.2.1   Low manufacturing cost of medicines to drive demand 231

TABLE 190         CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    232

TABLE 191         CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             232

TABLE 192         CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       233

TABLE 193         CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    233

TABLE 194         CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          234

TABLE 195         CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             234

TABLE 196         CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          235

TABLE 197         CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          235

8.4.3      JAPAN  235

8.4.3.1   Rising geriatric population to support market growth   235

TABLE 198         JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    236

TABLE 199        JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          237

TABLE 200         JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             237

TABLE 201         JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    238

TABLE 202         JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          238

TABLE 203        JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          239

TABLE 204         JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     239

TABLE 205         JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          240

8.4.4      INDIA   240

8.4.4.1   Increasing number of clinical trials to drive market      240

TABLE 206         INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    241

TABLE 207        INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          241

TABLE 208         INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             242

TABLE 209         INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    242

TABLE 210         INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          243

TABLE 211        INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          243

TABLE 212         INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     244

TABLE 213         INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          244

8.4.5      AUSTRALIA       245

8.4.5.1   Large number of research institutes make Australia favorable location for drug discovery             245

TABLE 214         AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    245

TABLE 215         AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             246

TABLE 216         AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    246

TABLE 217         AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 247

TABLE 218         AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             247

TABLE 219         AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             248

TABLE 220         AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          248

TABLE 221        AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          249

8.4.6      SOUTH KOREA 249

8.4.6.1   Growth in clinical trial activities to propel market        249

TABLE 222         SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 250

TABLE 223         SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       251

TABLE 224         SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    251

TABLE 225         SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 252

TABLE 226         SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       252

TABLE 227         SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       253

TABLE 228         SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             253

TABLE 229         SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             254

8.4.7      REST OF ASIA PACIFIC  254

TABLE 230         REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 255

TABLE 231         REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    255

TABLE 232         REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 256

TABLE 233         REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)   256

TABLE 234         REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    257

TABLE 235         REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    257

TABLE 236        REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       258

TABLE 237         REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    258

8.5         LATIN AMERICA             259

8.5.1      LATIN AMERICA: RECESSION IMPACT   259

TABLE 238         LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     260

TABLE 239         LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 260

TABLE 240         LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    261

TABLE 241         LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    261

TABLE 242         LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 262

TABLE 243         LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       262

TABLE 244         LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    263

TABLE 245         LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             263

TABLE 246         LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             264

TABLE 247         LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     264

8.5.2      BRAZIL 265

8.5.2.1   Rising adoption of emerging medical technologies to drive market           265

TABLE 248         BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    266

TABLE 249         BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             266

TABLE 250         BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       267

TABLE 251         BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    267

TABLE 252        BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          268

TABLE 253         BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             268

TABLE 254         BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          269

TABLE 255         BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          269

8.5.3      MEXICO             270

8.5.3.1   Government initiatives and robust supply to drive market          270

TABLE 256         MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    271

TABLE 257         MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             271

TABLE 258         MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       272

TABLE 259         MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    272

TABLE 260         MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             273

TABLE 261         MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             273

TABLE 262         MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          274

TABLE 263         MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          274

8.5.4      REST OF LATIN AMERICA          275

TABLE 264         REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          275

TABLE 265         REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 276

TABLE 266         REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 276

TABLE 267         REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)   277

TABLE 268         REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    277

TABLE 269         REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 278

TABLE 270         REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    278

TABLE 271         REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    279

8.6         MIDDLE EAST & AFRICA             279

8.6.1      MIDDLE EAST & AFRICA: RECESSION IMPACT   280

TABLE 272         MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)        280

TABLE 273         MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 281

TABLE 274         MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    281

TABLE 275         MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 282

TABLE 276         MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)   282

TABLE 277         MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    283

TABLE 278         MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    283

TABLE 279         MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    284

TABLE 280         MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    284

TABLE 281         MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)     285

8.6.2      GCC      285

8.6.2.1   Supportive government initiatives to aid market growth             285

TABLE 282         GCC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)       286

TABLE 283         GCC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          286

TABLE 284         GCC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)             287

TABLE 285         GCC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)    287

TABLE 286         GCC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          288

TABLE 287         GCC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          288

TABLE 288         GCC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     289

TABLE 289         GCC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)     289

8.6.3      REST OF MIDDLE EAST & AFRICA           290

TABLE 290         REST OF MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)          290

TABLE 291         REST OF MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 291

TABLE 292         REST OF MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)              291

TABLE 293         REST OF MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)   292

TABLE 294         REST OF MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 292

TABLE 295         REST OF MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 293

TABLE 296         REST OF MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 293

TABLE 297         REST OF MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 294

9            COMPETITIVE LANDSCAPE       295

9.1         INTRODUCTION            295

9.2         RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS        296

FIGURE 42         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: STRATEGIES ADOPTED 296

9.3         REVENUE SHARE ANALYSIS       297

FIGURE 43         REVENUE ANALYSIS FOR KEY PLAYERS (2018–2022)        297

9.4         MARKET SHARE ANALYSIS         298

FIGURE 44         MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)        298

TABLE 298         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION       298

9.5         COMPANY EVALUATION MATRIX: KEY PLAYERS            299

9.5.1      STARS  300

9.5.2      PERVASIVE PLAYERS     300

9.5.3      EMERGING LEADERS    300

9.5.4      PARTICIPANTS 300

FIGURE 45         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 301

9.5.5      COMPANY FOOTPRINT 302

9.5.5.1   Overall footprint  302

FIGURE 46         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: OVERALL FOOTPRINT  302

9.5.5.2   Service footprint  303

TABLE 299         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE FOOTPRINT    303

9.5.5.3   End-user footprint             304

TABLE 300         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: END-USER FOOTPRINT 304

9.5.5.4   Regional footprint              305

TABLE 301         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL FOOTPRINT             305

9.6         COMPANY EVALUATION MATRIX: START-UPS/SMES     306

9.6.1      PROGRESSIVE COMPANIES       306

9.6.2      DYNAMIC COMPANIES 306

9.6.3      RESPONSIVE COMPANIES          306

9.6.4      STARTING BLOCKS       306

FIGURE 47         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023       307

9.6.5      COMPETITIVE BENCHMARKING            308

TABLE 302         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES         308

TABLE 303         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES  309

9.7         VALUATION AND FINANCIAL METRICS OF HEALTHCARE ANALYTICAL TESTING SERVICE VENDORS    310

FIGURE 48         EV/EBITDA OF KEY VENDORS   310

9.8         BRAND/PRODUCT COMPARATIVE ANALYSIS    311

FIGURE 49         BRAND/PRODUCT COMPARATIVE ANALYSIS OF KEY PLAYERS, BY SERVICE TYPE          311

9.8.1      EUROFINS SCIENTIFIC  312

9.8.2      WUXI APPTEC  312

9.8.3      CHARLES RIVER LABORATORIES            312

9.8.4      SGS S.A. 312

9.8.5      LABORATORY CORPORATION OF AMERICA HOLDINGS             313

9.9         COMPETITIVE SCENARIO          313

9.9.1      SERVICE LAUNCHES     313

TABLE 304         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2024          313

9.9.2      DEALS  314

TABLE 305         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEALS, JANUARY 2020–MARCH 2024       314

TABLE 306         HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: EXPANSIONS, JANUARY 2020–MARCH 2024         315

10          COMPANY PROFILES    318

10.1       KEY PLAYERS   318

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

10.1.1    EUROFINS SCIENTIFIC  318

TABLE 307         EUROFINS SCIENTIFIC: COMPANY OVERVIEW  318

FIGURE 50         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)    319

TABLE 308         EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED          319

TABLE 309         EUROFINS SCIENTIFIC: DEALS  321

10.1.2    LABORATORY CORPORATION OF AMERICA HOLDINGS             323

TABLE 310         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW  323

FIGURE 51         LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)    324

TABLE 311         LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED   324

TABLE 312         LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS  325

TABLE 313         LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS    326

10.1.3    WUXI APPTEC  327

TABLE 314         WUXI APPTEC: COMPANY OVERVIEW   327

FIGURE 52         WUXI APPTEC: COMPANY SNAPSHOT (2022)     328

TABLE 315         WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED              328

TABLE 316         WUXI APPTEC: SERVICE LAUNCHES      329

TABLE 317         WUXI APPTEC: DEALS  330

TABLE 318         WUXI APPTEC: EXPANSIONS     330

10.1.4    CHARLES RIVER LABORATORIES            332

TABLE 319         CHARLES RIVER LABORATORIES: COMPANY OVERVIEW              332

FIGURE 53         CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)              333

TABLE 320         CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED   333

TABLE 321         CHARLES RIVER LABORATORIES: SERVICE LAUNCHES  334

TABLE 322         CHARLES RIVER LABORATORIES: DEALS            335

10.1.5    SGS S.A. 338

TABLE 323         SGS S.A.: COMPANY OVERVIEW 338

FIGURE 54         SGS S.A.: COMPANY SNAPSHOT (2023)  339

TABLE 324         SGS S.A.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 339

TABLE 325         SGS S.A.: DEALS 341

TABLE 326         SGS S.A.: OTHER DEVELOPMENTS         342

10.1.6    THERMO FISHER SCIENTIFIC INC.          344

TABLE 327         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              344

FIGURE 55         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)   345

TABLE 328         THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   345

TABLE 329         THERMO FISHER SCIENTIFIC INC.: DEALS          346

TABLE 330         THERMO FISHER SCIENTIFIC INC.: EXPANSIONS            347

10.1.7    MEDPACE, INC. 348

TABLE 331         MEDPACE, INC.: COMPANY OVERVIEW 348

FIGURE 56         MEDPACE, INC.: COMPANY SNAPSHOT (2022)   348

TABLE 332         MEDPACE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              349

10.1.8    SARTORIUS AG 350

TABLE 333         SARTORIUS AG: COMPANY OVERVIEW 350

FIGURE 57         SARTORIUS AG: COMPANY SNAPSHOT (2022)   351

TABLE 334         SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED              351

TABLE 335         SARTORIUS AG: DEALS 352

10.1.9    INTERTEK GROUP PLC 353

TABLE 336         INTERTEK GROUP PLC: COMPANY OVERVIEW 353

FIGURE 58         INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022)   354

TABLE 337         INTERTEK GROUP PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED          354

TABLE 338         INTERTEK GROUP PLC: DEALS 357

TABLE 339         INTERTEK GROUP PLC: EXPANSIONS    357

10.1.10  MERCK KGAA   358

TABLE 340         MERCK KGAA: COMPANY OVERVIEW    358

FIGURE 59         MERCK KGAA: COMPANY SNAPSHOT (2022)      359

TABLE 341         MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED              359

TABLE 342         MERCK KGAA: SERVICE LAUNCHES       360

TABLE 343         MERCK KGAA: DEALS   360

TABLE 344         MERCK KGAA: EXPANSIONS      361

TABLE 345         MERCK KGAA: OTHER DEVELOPMENTS             361

10.1.11  SOURCE BIOSCIENCE    363

TABLE 346         SOURCE BIOSCIENCE: COMPANY OVERVIEW    363

FIGURE 60         SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2022)      364

TABLE 347         SOURCE BIOSCIENCE: PRODUCTS/SERVICES/SOLUTIONS OFFERED          364

TABLE 348         SOURCE BIOSCIENCE: SERVICE LAUNCHES       365

TABLE 349         SOURCE BIOSCIENCE: EXPANSIONS      365

10.1.12  ICON PLC          366

TABLE 350         ICON PLC: COMPANY OVERVIEW           366

FIGURE 61         ICON PLC: COMPANY SNAPSHOT (2022)             366

TABLE 351         ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED              367

TABLE 352         ICON PLC: DEALS          368

10.1.13  ALS       369

TABLE 353         ALS: COMPANY OVERVIEW        369

FIGURE 62         ALS: COMPANY SNAPSHOT (2022)          370

TABLE 354         ALS: PRODUCTS/SERVICES/SOLUTIONS OFFERED         370

TABLE 355         ALS: DEALS       371

10.1.14  FRONTAGE LABORATORIES, INC.           372

TABLE 356         FRONTAGE LABORATORIES, INC.: COMPANY OVERVIEW              372

FIGURE 63         FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2022)   373

TABLE 357         FRONTAGE LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   373

TABLE 358         FRONTAGE LABORATORIES, INC.: DEALS           375

TABLE 359         FRONTAGE LABORATORIES, INC.: OTHER DEVELOPMENTS              376

10.1.15  STERIS 377

TABLE 360         STERIS: COMPANY OVERVIEW  377

FIGURE 64         STERIS: COMPANY SNAPSHOT (2023)    378

TABLE 361         STERIS: PRODUCTS/SERVICES/SOLUTIONS OFFERED   378

10.1.16  IQVIA INC.         380

TABLE 362         IQVIA INC.: COMPANY OVERVIEW         380

FIGURE 65         IQVIA INC.: COMPANY SNAPSHOT (2023)           381

TABLE 363         IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              381

TABLE 364         IQVIA INC.: OTHER DEVELOPMENTS    382

10.1.17  ELEMENT MATERIALS TECHNOLOGY   383

TABLE 365         ELEMENT MATERIALS TECHNOLOGY: COMPANY OVERVIEW              383

TABLE 366         ELEMENT MATERIALS TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED   383

TABLE 367         ELEMENT MATERIALS TECHNOLOGY: SERVICE LAUNCHES              384

TABLE 368         ELEMENT MATERIALS TECHNOLOGY: DEALS   384

TABLE 369         ELEMENT MATERIALS TECHNOLOGY: EXPANSIONS     385

10.1.18  PACE ANALYTICAL SERVICES   386

TABLE 370         PACE ANALYTICAL SERVICES: COMPANY OVERVIEW    386

TABLE 371         PACE ANALYTICAL SERVICES: PRODUCTS/SERVICES/SOLUTIONS OFFERED   386

TABLE 372         PACE ANALYTICAL SERVICES: DEALS    388

TABLE 373         PACE ANALYTICAL SERVICES: OTHER DEVELOPMENTS              390

10.1.19  ALMAC GROUP 391

TABLE 374         ALMAC GROUP: COMPANY OVERVIEW 391

TABLE 375         ALMAC GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED              391

TABLE 376         ALMAC GROUP: SERVICE LAUNCHES    392

TABLE 377         ALMAC GROUP: EXPANSIONS   392

10.1.20  PHARMARON   393

TABLE 378         PHARMARON: COMPANY OVERVIEW    393

TABLE 379         PHARMARON: PRODUCTS/SERVICES/SOLUTIONS OFFERED              393

TABLE 380         PHARMARON: DEALS    394

10.2       OTHER PLAYERS           395

10.2.1    SYNEOS HEALTH           395

TABLE 381         SYNEOS HEALTH: COMPANY OVERVIEW            395

10.2.2    PAREXEL INTERNATIONAL (MA) CORPORATION           396

TABLE 382         PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW        396

10.2.3    LGC LIMITED   397

TABLE 383         LGC LIMITED: COMPANY OVERVIEW    397

10.2.4    CELERION         398

TABLE 384         CELERION: COMPANY OVERVIEW         398

10.2.5    BIOAGILYTIX    399

TABLE 385         BIOAGILYTIX: COMPANY OVERVIEW    399

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11          APPENDIX         400

11.1       DISCUSSION GUIDE      400

11.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             405

11.3       CUSTOMIZATION OPTIONS      407

11.4       RELATED REPORTS       407

11.5       AUTHOR DETAILS         408